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Figure. Genetic variations in complement associated genes (HSCT recipient DNA). Figure shows a “heat map” of gene variants in recipients with and without TMA: each
column represents a gene,with heterozygous variants shaded light blue and homozygous variants shaded red. Each row is a single patient, illustrating thewide distribution
of variants in multiple genes in the TMA cases, while few variants are seen in the cases without TMA.
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Background: Transplant associated thrombotic micro-
angiopathy (TMA) is frequent after HSCT, and in severe cases
causes signiﬁcant morbidity and mortality. Currently there
are no data addressing individual susceptibility to transplant
associated TMA. Frequent genetic variants in ADAMTS13 and
complement genes have been described in other micro-
angiopathies such as aHUS and TTP. We hypothesized that
polymorphic variants in complement genes increase sus-
ceptibility to transplant associated TMA.
Methods: 90 consecutive allogeneic HSCT patients were
enrolledonaprospective TMAbiomarker studyand categorized
as having TMA or no TMA using rigorous diagnostic criteria
(Jodele et al, Blood 2014). Genomic DNAwas isolated from pre-
HSCT recipient blood. We used a candidate gene approach to
identify 12 geneswithin the complement pathway likely to play
a role in terminal complement activation, the likely effector
mechanism for vascular damage in TMA. All exons, ﬂanking
intronic and untranslated regions of ADAMTS13, CFH, CFI, CFB,
MCB, THBD, C3, C5, CFD, CFHR1, CFHR3 and CFHR5 were
sequenced using next generation sequencing technology. The
resulting sequence reads were aligned against the reference
DNA sequence and the variants were detected using NextGENesoftware. Observed variants were compared against dbSNP
(NCBI). Novel variants were further evaluated using laboratory
developed bioinformatic tools. Eight variants previously
described as likely pathogenic and 34 variants of unknown
pathogenic signiﬁcancewere identiﬁed. Resultswere compared
in patients with and without TMA.
Results: 77 patients had DNA available for analysis (34 with
TMA and 43 without TMA); 23 of 34 (68%) subjects with TMA
had complement gene variants as compared to 4 of 43 (9%)
controls without TMA (p<0.0001). Figure shows a “heat map”
of gene variants in recipients with and without TMA
illustrating the wide distribution of variants in multiple
genes in the TMA cases, while few variants are seen in those
without TMA. Likely pathogenic variants previously
described in other microangiopathies were seen in
ADAMTS13 (n¼2), CFH (n¼2), CFB (n¼1), CFHR5 (n¼1) and
CFI (n¼3), all in recipients with TMA. No known pathogenic
variants were seen in subjects without TMA. Two recipients
with TMA had homozygous deletion of CFHR3/R1, which was
not seen in the recipients without TMA. The median number
of gene variants (of known or unknown signiﬁcance) seen in
recipients with TMAwas 1 (0-7), and 0 (0-2) in those without
TMA (p<0.0001). Two subjects had 5 variants and one 7
variants and all three had fatal TMA.
Conclusion: The incidence of complement gene variants was
higher in patients with TMA as compared to patients without
TMA, indicating that genetic susceptibility importantly alters
risk. Additional larger studies are needed to deﬁne the
mechanistic importance of variants of unknown clinical
signiﬁcance.
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